Briefly Business: Govt appoints RV Verma as PFRDA member

Dublin-based Amarin Pharma has filed a patent infringement case against Dr. Reddy’s Laboratories.

By: Press Trust of India | Published: May 5, 2014 12:32 am

NEW DELHI: The government has appointed RV Verma as a member of the Pension Fund Regulatory and Development Authority (PFRDA). Verma has been appointed as Whole-Time Member (Finance) in the PFRDA, the finance ministry said in a notification. He is currently chairman and MD of the National Housing Bank, the regulator for housing finance companies.

FPIs can invest $81 bn in debt securities

NEW DELHI: Foreign Portfolio Investors (FPIs), a newly created class for overseas investors, will be able to invest up to $81 billion in government and corporate debt securities in India. This would include investments up to $30 billion in government debt and up to $51 billion in corporate debt securities under the new FPI regime, which would come into force from next month.

Amarin files patent case against DRL

HYDERABAD: Dublin-based Amarin Pharma has filed a patent infringement case against Dr. Reddy’s Laboratories alleging that the latter is attempting to come out with generic versions of its patented drug Vascepa. Amarin alleged that the Indian drug maker’s Abbreviated New Drug Application (ANDA), seeking to market the generic version, would infringe the patent of Vascepa on 16 counts.

Taj Group wins battle over spa trademark  

NEW DELHI: The Taj Group of Hotels has won a legal battle in the Delhi High Court over trademark ‘JIVA’ used for spa services in its hotels across the globe. Justice Sanjeev Sachdeva restrained businessman Ashwajeet Garg from using “deceptively similar” trademark ‘ZIVA’ for providing similar spa services in hotels in India.

‘Decision on Birla after verifying Parakh facts’

NEW DELHI: A decision by CBI on summoning Aditya Birla group chairman Kumar Manglam Birla will be taken only after the agency corroborates statements made by former coal secretary PC Parakh. “We are analysing and corroborating the statements made by Parakh with our records and a decision whether to question Birla will be taken after that,” CBI sources said.

For all the latest Business News, download Indian Express App

  1. No Comments.